J&J, Vivus patent suit ends

Share this article:

Johnson & Johnson's Janssen subsidiary has walked away from a lawsuit against drugmaker Vivus over patents using the anti-seizure medication topiramate for a variety of medical conditions.

Vivus, in turn, has agreed to pay a one-time fee and royalty on its FDA-approved weight-loss drug Qsymia, which combines phentermine and topiramate.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Channel

This compelling e-book shares a wealth of insights designed to help members of sales forces connect with elusive HCPs. An expanded version has also been created that includes video interviews and other multimedia content. Click here for access.